Market Overview

3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Share:
3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR.

The Analyst

B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target.

The Thesis

Uniqure's AMT-061 can potentially disrupt and transform hemophilia B treatment on three fronts, Kumar said in the initiation note:

  • The company's recently issued patent should eliminate any concerns tied to the patent estate, which makes the company "the dominant firm" in hemophilia B AAV GT from an intellectual property point of view, the analyst said. 
  • Preclinical and clinical data suggests an AAV5-based GT has a substantially modest neutralizing antibody rate, and the company's Phase 3 study of its AMT-061 should show the potential to be used in almost all hemophilia B patients, Kumar said. 
  • The regulatory environment at the FDA suggests that hemophilia factor production could serve as a surrogate endpoint for approval, with downstream functional measures included bleed rates as a post-approval metric, the analyst said. This bodes well for AMT-061's rapid approval from the regulatory bodies, he said. 

From an intellectual property, scientific and regulatory point of view, Uniqure boasts many advantages in hemophilia B, according to B. Riley FBR. 

Price Action

Uniqure shares were rallying more than 13 percent to $38.39 at the time of publication Thursday afternoon. 

Related Links:

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Latest Ratings for QURE

DateFirmActionFromTo
Apr 2019Initiates Coverage OnOverweight
Mar 2019Initiates Coverage OnOutperform
Mar 2019MaintainsOutperformOutperform

View More Analyst Ratings for QURE
View the Latest Analyst Ratings

Posted-In: AMT 061 B Riley FBRAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (QURE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CRCMaintains24.0
ZIONMaintains56.0
AMTDMaintains57.0
NEPMaintains52.0
LIIMaintains293.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

China Answers Quietly On Trade

Amazon Breaks Walgreens' Bullish Cycle, More Downside To Come